An Ebola signature

The team has successfully defined a “formula” capable of predicting the efficacy and safety of new Ebola virus vaccines.

By studying the plasma from 115 Genevan volunteers who took part in a clinical trial of a candidate virus in 2015, researchers observed that the concentration of five inflammation markers was sufficient to understand the gist of the immune response to the virus.

This promising formula is a practical and easy-to-use equation: addition of the concentrations of five substances whose activity is controlled by the monocytes – a category of white blood cells known for fighting the Ebola virus in the human body.

Find an actor

BioAlps World Visibitlity Package 201918.03.2019

A yearly international programme for our affiliated companies to increase their visibility.

"Bristol-Myers Squibb to Acquire Celgene for About Billion"

"The combined company will have nine products with more than billion in annual sales"
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn